Baillie Gifford & Co. Purchases 138,387 Shares of Penumbra, Inc. (NYSE:PEN)

Baillie Gifford & Co. boosted its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 23.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 730,233 shares of the company's stock after acquiring an additional 138,387 shares during the quarter. Baillie Gifford & Co. owned approximately 1.90% of Penumbra worth $173,416,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. True Wealth Design LLC bought a new position in Penumbra during the third quarter valued at approximately $26,000. UMB Bank n.a. raised its position in shares of Penumbra by 57.4% in the fourth quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $46,000 after purchasing an additional 70 shares during the period. Mather Group LLC. raised its position in shares of Penumbra by 208.0% in the fourth quarter. Mather Group LLC. now owns 308 shares of the company's stock valued at $73,000 after purchasing an additional 208 shares during the period. Advisors Asset Management Inc. raised its position in shares of Penumbra by 11.5% in the third quarter. Advisors Asset Management Inc. now owns 416 shares of the company's stock valued at $81,000 after purchasing an additional 43 shares during the period. Finally, Blue Trust Inc. raised its position in shares of Penumbra by 808.9% in the third quarter. Blue Trust Inc. now owns 509 shares of the company's stock valued at $92,000 after purchasing an additional 453 shares during the period. Institutional investors own 88.88% of the company's stock.

Penumbra Stock Performance

PEN traded down $0.94 during trading on Thursday, reaching $302.82. 683,697 shares of the company's stock were exchanged, compared to its average volume of 527,591. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The company has a quick ratio of 3.25, a current ratio of 5.82 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average price of $257.15 and a 200 day moving average price of $226.51. The company has a market capitalization of $11.62 billion, a P/E ratio of 890.64, a PEG ratio of 1.99 and a beta of 0.53.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.09. The company had revenue of $315.52 million during the quarter, compared to analysts' expectations of $311.63 million. Penumbra had a return on equity of 9.73% and a net margin of 1.17%. As a group, analysts predict that Penumbra, Inc. will post 3.86 earnings per share for the current fiscal year.

Insider Buying and Selling at Penumbra

In related news, CAO Lambert Shiu sold 1,798 shares of Penumbra stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $242.56, for a total value of $436,122.88. Following the completion of the transaction, the chief accounting officer now directly owns 20,682 shares of the company's stock, valued at $5,016,625.92. The trade was a 8.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $244.49, for a total value of $146,694.00. Following the completion of the transaction, the executive vice president now directly owns 63,444 shares of the company's stock, valued at $15,511,423.56. This represents a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,219 shares of company stock valued at $4,426,439. 5.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PEN has been the topic of a number of recent analyst reports. UBS Group lifted their price target on shares of Penumbra from $305.00 to $320.00 and gave the company a "buy" rating in a research report on Wednesday. BTIG Research lifted their price target on shares of Penumbra from $232.00 to $270.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Canaccord Genuity Group raised their price objective on shares of Penumbra from $323.00 to $340.00 and gave the stock a "buy" rating in a research note on Wednesday. Wells Fargo & Company raised their price objective on shares of Penumbra from $275.00 to $305.00 and gave the stock an "overweight" rating in a research note on Wednesday. Finally, Citigroup raised their price objective on shares of Penumbra from $220.00 to $245.00 and gave the stock a "neutral" rating in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $292.64.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.